Brief: Paradigm Biopharmaceuticals Posts FY Loss Attributable Of A$18.8 Million
29/08/2025 11:38
Aug 29 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX: FY LOSS ATTRIBUTABLE A$18.8 MILLION FY REVENUE FROM CONTINUING ACTIVITIES A$7.1 MILLION Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt